An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients.

about

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients.

Item

http://www.wikidata.org/entity/Q38729853

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

An ensemble-based Cox proporti ...... state cancer (mCRPC) patients.

@en

type

Item

label

An ensemble-based Cox proporti ...... state cancer (mCRPC) patients.

@en

prefLabel

An ensemble-based Cox proporti ...... state cancer (mCRPC) patients.

@en

P1476

An ensemble-based Cox proporti ...... state cancer (mCRPC) patients.

@en

P2093

Brooke Fridley

http://www.w3.org/2001/XMLSchema#string

Devin Koestler

http://www.w3.org/2001/XMLSchema#string

Joseph Usset

http://www.w3.org/2001/XMLSchema#string

Junqiang Dai

http://www.w3.org/2001/XMLSchema#string

Prabhakar Chalise

http://www.w3.org/2001/XMLSchema#string

Rama Raghavan

http://www.w3.org/2001/XMLSchema#string

Richard Meier

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

P304

2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.8226.1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

S Ellis

Stefan Graw

P577

2016-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28413609

http://www.w3.org/2001/XMLSchema#string

P932

5365222

http://www.w3.org/2001/XMLSchema#string